Persistent selling pressure weighs on UiPath stock, sending it lower

Traders Union
All News
Financial News
UiPath drops 3.85% to $10.36 today

Highlights

UiPath approved a new $500 million share buyback after completing a prior $1 billion program, directly reducing equity supply.
Expansion in South Korea via a Microsoft partnership and regional cloud solutions aims to increase enterprise adoption, while revenue grew 14% year over year.
Shares trade below key technical averages amid persistent selling pressure, with an expected five-session range of $10.20 to $10.90 and downside risk prevailing.

Buyback approval and product expansion counter persistent selling pressure

UiPath approved a new $500 million share buyback program after completing a previous $1 billion repurchase, directly reducing the equity float and providing mechanical support for per-share value. The company broadened its Automation Cloud presence in South Korea through a partnership with Microsoft, enabling local data residency and potentially increasing its regional enterprise client base. Continued product initiatives, such as the launch of Intelligent Xtraction and Processing on Google Cloud Marketplace, and reported 14% year-over-year revenue growth point to positive underlying fundamentals, though price action has remained under broader selling pressure.

Mixed momentum signals amid persistent downside pressure at key levels

Technically, key levels for PATH include the MA-20 at $10.43, MA-50 at $10.80, and MA-200 marking longer-term resistance at $12.99. The Ichimoku Kijun at $10.25 suggests immediate support just under current levels. Momentum signals remain conflicted: the MACD signals strong sell while the ADX is neutral and weak. RSI on the daily chart is in buy territory, but Stoch RSI is showing overbought readings near extremes; CCI appears neutral. Bull/Bear Power (BBP) on the daily timeframe shows strong buy, favoring buyers intraday, but shorter timeframes reflect selling pressure, and the Awesome Oscillator does not confirm a directional trend. With intraday trading near the day’s lows between $10.31 and $10.58 and high daily volatility, prices face steady downward pressure after the open with mixed oscillator sentiment highlighting short-term divergence.

Downside risk dominates short-term as key indicators stay bearish

For the next five trading sessions, the anticipated volatility band is $10.20 to $10.90. The probability of a move higher is assessed as very low (below 20%), with further downside more likely in the short term given all key weekly indicators remain aligned with sellers. The baseline expectation is for price to consolidate sideways within the cited range as buyers and sellers remain indecisive. A break above $10.90 would signal a possible recovery, while a sustained move below $10.20 would expose the stock to additional downside risk, potentially prompting a test of lower support levels.

Viktoras Karapetjanc, Traders Union analyst, sees UiPath’s fundamentals as resilient, with an expanded buyback program and product growth underpinning long-term value. He acknowledges current price weakness and mixed momentum signals but remains constructive on the company’s strategic advances and revenue growth. The analyst believes consolidation is most likely in the near term, with further downside risk if $10.20 breaks. "While short-term selling persists, I think UiPath’s fundamentals and capital return measures make it a stock to watch for a potential rebound if market sentiment improves."

Earlier, analysts noted that UiPath was experiencing persistent seller pressure and a lack of clear bullish momentum despite supportive corporate actions. The current session further reinforces this cautious outlook, with short-term technicals and continued volatility underscoring the need to monitor for a potential downside break below $10.20 as a key risk in the days ahead.

Source of Data: PATH Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.